DOM-TERAZOSIN 2 MG
TERAZOSIN (TERAZOSIN HYDROCHLORIDE) : 2 MG · DIN 02243747 · DOMINION PHARMACAL
Health Canada status: CANCELLED POST MARKET
What is DOM-TERAZOSIN?
DOM-TERAZOSIN 2 MG contains TERAZOSIN (TERAZOSIN HYDROCHLORIDE) : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02243747, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOM-TERAZOSIN used for?
Treatment of mild to moderate hypertension and symptomatic treatment of benign prostatic hyperplasia (BPH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243747 |
|---|---|
| Brand name | DOM-TERAZOSIN |
| Generic / active ingredient | TERAZOSIN (TERAZOSIN HYDROCHLORIDE) : 2 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 2 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04CA03 TERAZOSIN |
| AHFS class | 24:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-May-2025 |
| Original market date | 2001-10-31 00:00:00 |
How is it administered?
Initial dose: 1 mg at bedtime (must not be exceeded). Hypertension: Usual range 1-5 mg daily; max 20 mg. BPH: Stepwise increase at weekly intervals to 2, 5, or 10 mg once daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 17, but text ends at section 11).
How is it supplied?
Not explicitly detailed in provided text (mentions 1 mg, 2 mg, 5 mg, and 10 mg strengths).
Contraindications
Hypersensitivity to terazosin hydrochloride or its analogs. Patients with a history of micturition syncope should not receive Dom-TERAZOSIN.
Warnings and precautions
Can cause marked hypotension and syncope (first-dose effect). Avoid driving for 12 hours after initial dose or dose increase. Rule out prostatic cancer before BPH treatment.
What can be used instead?
Other Canadian products sharing ATC code G04CA03 TERAZOSIN. 8 of 57 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TERAZOSIN | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02234502 |
| APO-TERAZOSIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02234505 |
| APO-TERAZOSIN | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02234503 |
| APO-TERAZOSIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02234504 |
| PMS-TERAZOSIN | 1 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02243518 |
| PMS-TERAZOSIN | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02243521 |
| PMS-TERAZOSIN | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02243519 |
| PMS-TERAZOSIN | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02243520 |
| DOM-TERAZOSIN | 1 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243746 |
| DOM-TERAZOSIN | 10 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243749 |
Who else supplies TERAZOSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TERAZOSIN appears in 14 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.